Antiangiogenic treatment in hepatocellular carcinoma: the balance of efficacy and safety. - Wikidata - wikimedia - TriplyDB

Antiangiogenic treatment in hepatocellular carcinoma: the balance of efficacy and safety.

Antiangiogenic treatment in hepatocellular carcinoma: the balance of efficacy and safety.

http://www.wikidata.org/entity/Q38160838

about

Chemotherapeutic agents for the treatment of hepatocellular carcinoma: efficacy and mode of action Role of regorafenib as second-line therapy and landscape of investigational treatment options in advanced hepatocellular carcinoma Nonalcoholic steatohepatitis-related hepatocellular carcinoma: is there a role for the androgen receptor pathway?The role of hypoxia inducible factor-1 in hepatocellular carcinoma.TPX2 knockdown suppressed hepatocellular carcinoma cell invasion via inactivating AKT signaling and inhibiting MMP2 and MMP9 expression.Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance).Communicative reprogramming non-curative hepatocellular carcinoma with low-dose metronomic chemotherapy, COX-2 inhibitor and PPAR-gamma agonist: a phase II trial.Transarterial chemoembolization for hepatocellular carcinoma combined with portal vein tumor thrombosis

P2860

Q27693179-B395BE75-BFA8-46EE-B39A-87E920E90782 Q28070762-F06B25A6-8B7F-4FAB-AB28-3A44587DDC0D Q30234736-09EABD07-B832-4B81-95A9-51D0CC15BBBE Q33914603-BD59DECF-539B-476A-8A9E-2BA1B8B4F76C Q34130156-82783D19-848D-49CF-A4A2-6AB9359C121B Q39109076-BE37C67B-4249-418B-8DED-5C5F7B22181C Q47144193-13F7EE30-7CBE-4F73-9DB5-D88F85ED17B3 Q58605600-FE97C2C6-A67F-4D01-BF53-85FB5B426E5F

P2860

Antiangiogenic treatment in hepatocellular carcinoma: the balance of efficacy and safety.

http://www.wikidata.org/entity/Q38160838

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Antiangiogenic treatment in hepatocellular carcinoma: the balance of efficacy and safety.

@en

type

label

Antiangiogenic treatment in hepatocellular carcinoma: the balance of efficacy and safety.

@en

prefLabel

Antiangiogenic treatment in hepatocellular carcinoma: the balance of efficacy and safety.

@en

P1433

Q38160838-0F9726BF-2631-4509-B51E-E45B46E94ACB

P1476

Q38160838-74F67827-D177-4447-A156-3B323C520D2E

P2093

Q38160838-2648FD80-71C5-4623-83FA-DD13C3FD478A

Q38160838-C5C20043-64B2-4734-98A9-53411128DDD9

P2860

Q38160838-021D46E7-B6FA-4012-A7BD-9CBD42C71F95

Q38160838-0A7B8DC2-2563-4124-ADC4-640F79223628

Q38160838-0D299E28-AC6D-4EAF-9AD0-2947A1040438

Q38160838-0DB5E94E-4943-4396-AAD3-7A3C8F8EA8EE

Q38160838-0F051B81-8D7D-438B-B40D-7AF842AA61CC

Q38160838-132FAB41-3AD8-465C-AF21-2F1EBD111E55

Q38160838-15AD37BD-8432-4946-A649-EC29AF72BDB8

Q38160838-17BD638C-802D-4E53-9362-290D9D74EE7E

Q38160838-1865ADA6-E7A1-48E7-81D4-D47C6B1F4B7F

Q38160838-1BA18BE8-D96E-4F29-93EC-69E6AADA6690

P304

Q38160838-BE87467C-B32C-4B0F-99C2-BED9BA303108

P31

Q38160838-7B6BDFF5-6128-4AB8-B717-A8A968BBE02D

P356

Q38160838-440D2932-2605-40D2-9274-B4EDC863AEF8

P407

Q38160838-92F04291-4B31-421C-B5B1-F2E0908847EC

P478

Q38160838-E041A798-59BC-48C7-B5FE-01CD6B913A99

P50

Q38160838-F5829BC2-2BCE-4721-8E28-F3FA0F2764A3

P577

Q38160838-434E90E0-1079-49F6-93BF-B66676ABC71A

P5875

Q38160838-DC0A69FF-5A2E-450B-9906-B865F95B7E6C

P698

Q38160838-67AD5F0A-B8BF-430E-999D-69F7B88B866B

P932

Q38160838-24864067-42EF-475E-853C-23B1F20FB71B

P356

P1433

Cancer Management and Research

P1476

Antiangiogenic treatment in hepatocellular carcinoma: the balance of efficacy and safety.

@en

P2093

Joerg Trojan

http://www.w3.org/2001/XMLSchema#string

Martin-Walter Welker

http://www.w3.org/2001/XMLSchema#string

P2860

Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies

Sorafenib in advanced hepatocellular carcinoma

Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma

Management of HCC

Hepatocellular carcinoma: epidemiology and molecular carcinogenesis

Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

Hepatocellular carcinoma

Management of hepatocellular carcinoma

Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial

P304

337-347

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/CMAR.S35029

http://www.w3.org/2001/XMLSchema#string

P407

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Martin-Walter Welker

P577

2013-10-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

258350043

http://www.w3.org/2001/XMLSchema#string

P698

24204170

http://www.w3.org/2001/XMLSchema#string

P932

3804539

http://www.w3.org/2001/XMLSchema#string